ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5402, an important new study that researchers hope will expand understanding ...

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

Review the side-effects of Pramipexole as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Learn everything you need to know about Pramipexole-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

February 23, 2010 — The US Food and Drug Administration (FDA) has approved a new once-daily formulation of pramipexole dihydrochloride (Mirapex ER tablets, Boehringer Ingelheim Pharmaceuticals, Inc) ...

Renton, WA - A drug for Parkinson's disease, the dopamine agonist pramipexole (Mirapex, Boehringer Ingelheim), "offers hope to patients with fibromyalgia," say researchers reporting the first trial of ...

Two large, randomised, placebo-controlled studies presented at the inaugural conference of the World Association of Sleep Medicine (WASM; Berlin, Germany) in October demonstrate that pramipexole ...

SEATTLE -- Parkinson's disease patients did better taking two drugs than one in a pivotal trial, a researcher said here. Scores on standard tests improved more among patients taking a fixed-dose ...

Patients with Parkinson disease demonstrated significant reduction in depressive symptoms with citalopram and pramipexole, with pramipexole showing slightly more benefit in improving quality of life.

Pramipexole, a dopamine agonist, improves depressive symptoms in patients with Parkinson's disease (PD), and has the potential to become an important antidepressant treatment for these patients. The ...